Alkermes - ALKS Stock Forecast, Price & News

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Alkermes in the last year. There are currently 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ALKS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALKS, but not buy additional shares or sell existing shares.
View ALKS analyst ratings or view top-rated stocks.

7 Wall Street analysts have issued 12 month price objectives for Alkermes' shares. Their ALKS share price forecasts range from $25.00 to $36.00. On average, they predict the company's stock price to reach $30.63 in the next twelve months. This suggests a possible upside of 8.6% from the stock's current price.
View analysts price targets for ALKS or view top-rated stocks among Wall Street analysts.

Alkermes' stock was trading at $26.13 at the beginning of the year. Since then, ALKS shares have increased by 7.9% and is now trading at $28.19.
View the best growth stocks for 2023 here.

Alkermes saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 9,470,000 shares, an increase of 5.5% from the February 28th total of 8,980,000 shares. Based on an average daily trading volume, of 1,240,000 shares, the days-to-cover ratio is currently 7.6 days.
View Alkermes' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 26th 2023.
View our ALKS earnings forecast.

Alkermes plc (NASDAQ:ALKS) issued its earnings results on Thursday, February, 16th. The company reported $0.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.05 by $0.09. The company had revenue of $304.70 million for the quarter, compared to analysts' expectations of $289.80 million. Alkermes had a negative trailing twelve-month return on equity of 3.32% and a negative net margin of 14.23%. The company's revenue for the quarter was down 6.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.13 earnings per share.

ETFs with the largest weight of Alkermes (NASDAQ:ALKS) stock in their portfolio include AdvisorShares Psychedelics ETF (PSIL), Harbor Health Care ETF (MEDI), iShares Neuroscience and Healthcare ETF (IBRN), Psyk Etf (PSYK), First Trust NYSE Arca Biotechnology Index Fund (FBT), ALPS Medical Breakthroughs ETF (SBIO), Invesco Dynamic Biotechnology & Genome ETF (PBE) and Putnam BioRevolution ETF (SYNB).

Alkermes updated its FY 2023 earnings guidance on Monday, February, 20th. The company provided EPS guidance of 0-$0.23 for the period, compared to the consensus earnings per share estimate of $0.26. The company issued revenue guidance of $1.13 billion-$1.25 billion, compared to the consensus revenue estimate of $1.17 billion.

119 employees have rated Alkermes Chief Executive Officer Richard F. Pops on Glassdoor.com. Richard F. Pops has an approval rating of 84% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Alkermes investors own include Gilead Sciences (GILD), Netflix (NFLX), Pfizer (PFE), NVIDIA (NVDA), AbbVie (ABBV), Starbucks (SBUX), Intel (INTC), Johnson & Johnson (JNJ) and Tesla (TSLA).

Alkermes trades on the NASDAQ under the ticker symbol "ALKS."

Shares of ALKS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ALKS stock can currently be purchased for approximately $28.19.

Alkermes (NASDAQ:ALKS) has a market capitalization of $4.63 billion and generates $1.11 billion in revenue each year. The company earns $-158,270,000.00 in net income (profit) each year or ($0.96) on an earnings per share basis.

The company employs 2,280 workers across the globe.

Alkermes' mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE, DUBLIN L2, DUBLIN 4. The official website for the company is www.alkermes.com. The company can be reached via phone at (531) 772-8000, via email at investor_relations@alkermes.com, or via fax at 781-890-0524.